1. Home
  2. PRTC vs XERS Comparison

PRTC vs XERS Comparison

Compare PRTC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • XERS
  • Stock Information
  • Founded
  • PRTC 2015
  • XERS 2005
  • Country
  • PRTC United States
  • XERS United States
  • Employees
  • PRTC N/A
  • XERS N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRTC Health Care
  • XERS Health Care
  • Exchange
  • PRTC Nasdaq
  • XERS Nasdaq
  • Market Cap
  • PRTC 509.0M
  • XERS 444.0M
  • IPO Year
  • PRTC N/A
  • XERS 2018
  • Fundamental
  • Price
  • PRTC $22.55
  • XERS $3.09
  • Analyst Decision
  • PRTC Buy
  • XERS Buy
  • Analyst Count
  • PRTC 1
  • XERS 3
  • Target Price
  • PRTC $45.00
  • XERS $4.87
  • AVG Volume (30 Days)
  • PRTC 4.5K
  • XERS 1.9M
  • Earning Date
  • PRTC 08-28-2024
  • XERS 11-08-2024
  • Dividend Yield
  • PRTC N/A
  • XERS N/A
  • EPS Growth
  • PRTC N/A
  • XERS N/A
  • EPS
  • PRTC N/A
  • XERS N/A
  • Revenue
  • PRTC $468,000.00
  • XERS $187,361,000.00
  • Revenue This Year
  • PRTC N/A
  • XERS $20.35
  • Revenue Next Year
  • PRTC $139.60
  • XERS $16.14
  • P/E Ratio
  • PRTC N/A
  • XERS N/A
  • Revenue Growth
  • PRTC N/A
  • XERS 22.72
  • 52 Week Low
  • PRTC $17.08
  • XERS $1.69
  • 52 Week High
  • PRTC $34.00
  • XERS $3.64
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 59.26
  • XERS 49.74
  • Support Level
  • PRTC $20.61
  • XERS $2.82
  • Resistance Level
  • PRTC $22.83
  • XERS $3.12
  • Average True Range (ATR)
  • PRTC 0.69
  • XERS 0.18
  • MACD
  • PRTC 0.04
  • XERS -0.03
  • Stochastic Oscillator
  • PRTC 68.44
  • XERS 32.93

About PRTC PureTech Health plc

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Share on Social Networks: